{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-269557","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2026-06-12T20:32:03+00:00","discovered_at":"2026-06-12T20:33:00.721075+00:00","generated_at":"2026-06-12T20:53:02.146925+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lineage withdraws CIRM grant application for OPC1 SCI trial; annual meeting results disclosed","bullets":["Withdrew CIRM CLIN2 grant application for OPC1 after receiving comments; says DOSED clinical study unaffected.","Shareholders elected all seven director nominees, including Michael Mulroy, Dipti Amin, and Deborah Andrews.","Ratified Baker Tilly as auditor for FY2026 (163.8M for, 0.7M against) and approved advisory say-on-pay (88.3M for, 2.6M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-269557","json":"https://secwatch.observer/filing/0001193125-26-269557.json","markdown":"https://secwatch.observer/filing/0001193125-26-269557.md","text":"https://secwatch.observer/filing/0001193125-26-269557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/lctx-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:53:02.146925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03a4b3720c5cd60d99e4ae2368bf813ac6df99b9","claim":"Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers at the 2026-06-10 meeting.","evidence_excerpt":"3. Shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"6613e421cc802f8ddeae810dcd4384d54bd3fcf5","claim":"Lineage Cell Therapeutics, Inc. shareholders approved Election of seven nominees to the board of directors at the 2026-06-10 meeting.","evidence_excerpt":"1. Shareholders elected the seven nominees named below to the Company’s board to hold office until the Company’s 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"fff0799458c1c051c9dd8a079cf3b23bfec878d7","claim":"Lineage Cell Therapeutics, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"2. Shareholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}